Abstract:Alveolar echinococcosis (AE) is a chronic and fatal infectious parasitic disease, which has not been well-researched. Current recommended therapies for AE by the World Health Organization include complete removal of the infected tissue followed by two years of albendazole (ABZ), administered orally, which is the only effective first-line anti-AE drug. Unfortunately, in most cases, complete resection of AE lesions is impossible, requiring ABZ administration for even longer periods. Only one-third of patients experienced complete remission or cure with such treatments, primarily due to ABZ's low solubility and low bioavailability. To improve ABZ bioavailability, albendazole bile acid derivative (ABZ-BA) has been designed and synthesized. Its structure was identified by mass spectrometry and nuclear magnetic resonance. Its physicochemical properties were evaluated by wide-angle X-ray diffraction, differential scanning calorimetry, scanning electron microscopy, and polarizing microscopy; it was compared with ABZ to assess its solubilization mechanism at the molecular level. To avoid the effects of bile acid on the efficacy of albendazole, the inhibitory effect of ABZ-BA on protoscolex (PSCs)s was observed in vitro . The inhibitory effect of ABZ-BA on PSCs was evaluated by survival rate, ultrastructural changes, and the expression of key cytokines during PSC apoptosis. The results showed that ABZ-BA with 4-amino-1-butanol as a linker was successfully prepared. Physicochemical characterization demonstrated that the molecular arrangement of ABZ-BA presents a short-range disordered amorphous state, which changes the drug morphology compared with crystalline ABZ. The equilibrium solubility of ABZ-BA was 4-fold higher than ABZ in vitro . ABZ-BA relative bioavailability (F rel ) in Sprague-Dawley (SD) rats was 26-fold higher than ABZ in vivo . The inhibitory effect of ABZ-BA on PSCs was identical to that of ABZ, indicating that adding bile acid did not affect the efficacy of anti-echinococcosis. In the pharmacodynamics study, it was found that the ABZ-BA group had 2.7-fold greater than that of Albenda after 1 month of oral administration. The relative bioavailability of ABZ-BA is significantly better than ABZ due to the transformation of the physical state from a crystalline state to an amorphous state. Furthermore, sodium-dependent bile acid transporter (ASBT) expressed in the apical small intestine has a synergistic effect through the effective transport of bile acids. Therefore, we concluded that the NC formulation could potentially be developed to improve anti-AE drug therapy. Alveolar echinococcosis (AE) is a neglected zoonotic parasitic disease caused by Echinococcus multilocularis ( E . multilocularis ). This parasitic infection can cause severe damage to the liver, lungs, and other human or animal organs, which can be fatal if left untreated. The 10-year mortality rate for patients with untreated or improperly treated AE is greater than 90%. Therefore, AE is also called as "worm cancer". Benzimidazoles, including the first-line drug ABZ, are considered the only effective drug against AE. However, ABZ has a low and erratic oral bioavailability due to its low solubility,which has partially led to unsatisfactory clinical efficacy of this oral drug. In this study, albendazole bile acid derivatives were prepared to improve the anti- Echinococcus multilocularis effect. The synergistic effect of steric hindrance and transmembrane transport increased the equilibrium solubility of ABZ-BA in vitro by nearly 4-fold and the bioavailability in vivo by about 90-fold. The in vivo study demonstrated that the pharmacokinetic behavior of the ABZ-BA was superior to that of Albenda. In the pharmacodynamics study, it was also found that the ABZ-BA group had a significant therapeutic effect after 1 month of oral administration. This albendazole bile acid derivative provides an effective and translatable novel approach to oral drug therapy for chronic, fatal, and neglected parasitic infectious alveolar echinococcosis.

Tirapazamine combined with photodynamic therapy improves the efficacy of ABZSO nanoparticles on Echinococcosis granulosus via further enhancing "breaking-then-curing"

Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis

Breaking-then-curing strategy for efficient cystic echinococcosis therapy

Scolicidal and apoptotic activities of albendazole sulfoxide and albendazole sulfoxide-loaded PLGA-PEG as a novel nanopolymeric particle against Echinococcus granulosus protoscoleces

Suppressive effect of pseudolaric acid B on Echinococcus multilocularis involving regulation of TGF-β1 signaling in vitro and in vivo

Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms

An in vivo appraisal of Punica granatum peel extract's ultrastructural effect on cystic echinococcosis in mice

Improvement of Antialveolar echinococcosis efficacy of novel Albendazole-Bile acids Derivatives with Enhanced Oral Bioavailability

Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst

Effects of Photodynamic Therapy Alone or in Combination with Antifungal Agents on the Apoptosis of Planktonic and Biofilm Cells of Exophiala Dermatitidis

In vitro and ex vivo protoscolicidal effect of poly(amidoamine) nanoemulsion against Echinococcus granulosus

Transcriptome analysis uncovers the key pathways and candidate genes related to the treatment of Echinococcus granulosus protoscoleces with the repurposed drug pyronaridine

Improvement of Antialveolar Echinococcosis Efficacy of Albendazole by a Novel Nanocrystalline Formulation with Enhanced Oral Bioavailability

In Vitro and in Vivo Effects of 3-Bromopyruvate Against Echinococcus Metacestodes

Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond

In Vitro Efficacy of Ampelopsin Against Echinococcus Granulosus and Echinococcus Multilocularis

In Vitro and in Vivo Efficacies of Carbazole Aminoalcohols in the Treatment of Alveolar Echinococcosis.

Zinc Oxide and Magnesium-Doped Zinc Oxide Nanoparticles Ameliorate Murine Chronic Toxoplasmosis

Modulating Endogenous Oxygen Consumption Enhanced AIEgens‐Mediated Photodynamic Therapy against Advanced Bladder Tumor

Biomedical behaviors of CuO/γ-alumina/chitosan nanocomposites: Scolicidal and apoptotic effects on hydatid cysts protoscolices

In Vivo and in Vitro Efficacies of Mebendazole, Mefloquine and Nitazoxanide Against Cyst Echinococcosis